PE20030638A1 - Formulacion granular de montelukast sodico - Google Patents

Formulacion granular de montelukast sodico

Info

Publication number
PE20030638A1
PE20030638A1 PE2002001047A PE2002001047A PE20030638A1 PE 20030638 A1 PE20030638 A1 PE 20030638A1 PE 2002001047 A PE2002001047 A PE 2002001047A PE 2002001047 A PE2002001047 A PE 2002001047A PE 20030638 A1 PE20030638 A1 PE 20030638A1
Authority
PE
Peru
Prior art keywords
montelukast sodium
granular formulation
polylivine
refers
substrate
Prior art date
Application number
PE2002001047A
Other languages
English (en)
Inventor
Brian Down
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23329547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030638(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of PE20030638A1 publication Critical patent/PE20030638A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA GRANULACION ORAL DE MONTELUKAST SODICO, QUE COMPRENDE: UN SUBSTRATO QUE FLUYE LIBREMENTE REVESTIDO DE MONTELUKAST SODICO; DONDE, DICHO SUBSTRATO PUEDE SER: MANITOL DESHIDRATADO POR ASPERSION CON UN AGENTE AGLUTINANTE O PEARLITOL SD 200, SELECCIONANDOSE EL AGLUTINANTE DE: CELULOSA HIDROXIPROPILICA, METILCELULOSA HIDROXIPROPILICA, METILCELULOSA, ETILCELULOSA Y POLIVINILPIRROLIDONA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA FLUIDA Y DISPERSABLE QUE COMPRENDE LOS GRANULOS YA DESCRITOS
PE2002001047A 2001-10-26 2002-10-24 Formulacion granular de montelukast sodico PE20030638A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33954901P 2001-10-26 2001-10-26

Publications (1)

Publication Number Publication Date
PE20030638A1 true PE20030638A1 (es) 2003-07-21

Family

ID=23329547

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001047A PE20030638A1 (es) 2001-10-26 2002-10-24 Formulacion granular de montelukast sodico

Country Status (26)

Country Link
US (2) US20030096840A1 (es)
EP (1) EP1441701B1 (es)
JP (1) JP4420671B2 (es)
KR (1) KR101094084B1 (es)
CN (1) CN100591329C (es)
AT (1) ATE385781T1 (es)
AU (1) AU2002333134B2 (es)
BR (1) BR0213477A (es)
CA (1) CA2463947C (es)
CY (1) CY1107400T1 (es)
DE (1) DE60225040T2 (es)
DK (1) DK1441701T3 (es)
EC (1) ECSP045082A (es)
EG (1) EG24380A (es)
ES (1) ES2298431T3 (es)
HR (1) HRP20040367B1 (es)
HU (1) HUP0401670A3 (es)
IL (1) IL161299A0 (es)
MX (1) MXPA04003856A (es)
MY (1) MY148466A (es)
NO (1) NO20042167L (es)
PE (1) PE20030638A1 (es)
PT (1) PT1441701E (es)
SI (1) SI1441701T1 (es)
WO (1) WO2003035036A1 (es)
ZA (1) ZA200402584B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192660A1 (en) * 2003-03-12 2004-09-30 Mullally John P. Protocol for improving vision
AU2006224842B2 (en) * 2005-03-16 2011-09-29 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US9757455B2 (en) 2005-11-28 2017-09-12 Johnson & Johnson Consumer Inc. Oral therapeutic compound delivery system
PT1976522E (pt) 2005-12-30 2013-09-09 Krka Tovarna Zdravil D D Novo Mesto Composição farmacêutica contendo montelucaste
AU2006337648A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
CA2661576A1 (en) 2006-09-26 2008-04-03 Taro Pharmaceuticals North America, Inc. Stabilizing compositions for antibiotics and methods of use
CN102046202A (zh) * 2008-03-26 2011-05-04 塔罗制药北美有限公司 用于口服药剂的稳定脂质组合物
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
DK3085381T3 (en) 2008-05-21 2018-05-28 Ferring Bv ORODISPERSIBLE DESMOPRESSIN TO INCREASE THE INITIAL PERIOD OF SLEEP UNDERSTANDED BY NEW TURRY
WO2009153305A2 (en) * 2008-06-19 2009-12-23 Sandoz Ag Pharmaceutical compositions of montelukast sodium
WO2010021300A1 (ja) * 2008-08-18 2010-02-25 三菱商事フードテック株式会社 新規マンニトール打錠用賦形剤
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
RU2566269C2 (ru) 2010-03-29 2015-10-20 Ферринг Б.В. Быстрорастворимая фармацевтическая композиция
FR2967066B1 (fr) * 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
CN102085187B (zh) * 2011-01-27 2012-01-11 海南美大制药有限公司 孟鲁司特钠脂质体固体制剂
CN103842344B (zh) 2011-07-26 2016-08-03 太阳医药高级研究有限公司 基于喹啉、喹喔啉或苯并[c]噻唑的半胱氨酰白三烯拮抗剂
JP6174585B2 (ja) 2011-09-16 2017-08-02 フェリング ベスローテン フェンノートシャップ 速溶性医薬組成物
WO2013077829A1 (en) 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
KR20150030752A (ko) * 2012-07-12 2015-03-20 훼링 비.브이. 디클로페낙 제형
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US20140072628A1 (en) * 2012-09-12 2014-03-13 Glenmark Generics Ltd. Stable pharmaceutical composition of saxagliptin
CN103520129B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 一种孟鲁斯特钠脉冲释放制剂
CN103520136B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 孟鲁斯特钠脉冲胶囊及其制备方法
CN103520130B (zh) * 2013-10-15 2020-08-04 天垚医药科技发展（上海）有限公司 孟鲁斯特钠择时控释片及其制备方法
CN104644564A (zh) * 2013-11-25 2015-05-27 天津汉瑞药业有限公司 一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法
CN103655497B (zh) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
EP3096760A1 (en) 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN103720672B (zh) * 2014-01-26 2016-03-16 新疆特丰药业股份有限公司 孟鲁司特钠咀嚼片及其粉末直接压片制备方法
CN104840427B (zh) * 2014-02-13 2017-09-29 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
KR101892340B1 (ko) * 2015-03-13 2018-08-27 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
JP6489435B2 (ja) * 2015-04-20 2019-03-27 高田製薬株式会社 モンテルカストナトリウム顆粒製剤
CN107595783A (zh) * 2017-06-01 2018-01-19 合肥远志医药科技开发有限公司 一种孟鲁司特钠颗粒及其制备方法
CN109833302A (zh) * 2017-11-29 2019-06-04 扬子江药业集团有限公司 一种稳定的孟鲁司特钠咀嚼片及其制备方法
CN110787139A (zh) * 2018-08-01 2020-02-14 北京万全德众医药生物技术有限公司 一种孟鲁司特钠药物组合物
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
CN111110679A (zh) * 2018-10-31 2020-05-08 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
CN111249238A (zh) * 2020-01-19 2020-06-09 安徽省先锋制药有限公司 一种孟鲁司特钠颗粒制剂方法
WO2022011210A1 (en) * 2020-07-10 2022-01-13 Sean Downing Treatment for severe acute respiratory illness associated with coronavirus
CN111840233B (zh) * 2020-07-29 2022-05-06 浙江诺得药业有限公司 一种孟鲁司特钠固体分散体、其制备方法及其应用
CN114224847B (zh) * 2021-12-07 2023-09-15 哈尔滨珍宝制药有限公司 一种孟鲁司特钠颗粒的制备方法
CN114425040A (zh) * 2022-02-24 2022-05-03 佑华医药科技有限公司 一种孟鲁司特钠颗粒的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
NZ230763A (en) 1988-09-27 1991-10-25 Takeda Chemical Industries Ltd Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
ES2058546T3 (es) 1988-09-30 1994-11-01 Rhone Poulenc Rorer Ltd Formulaciones farmaceuticas granulares.
DE69005679T2 (de) * 1989-03-29 1994-06-23 Takeda Chemical Industries Ltd Zusammensetzung mit einer Verbindung der Vitamin B-Gruppe und ihre Herstellung.
JP2800242B2 (ja) 1989-03-30 1998-09-21 大正製薬株式会社 粒剤の製造方法
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH0967247A (ja) 1995-08-31 1997-03-11 Taisho Pharmaceut Co Ltd 均一な微粒子製剤の製造方法
CA2236175A1 (en) * 1995-11-02 1997-05-09 Merck Frosst Canada Incorporated New technology for wet granulation
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
ATE331522T1 (de) 1997-12-23 2006-07-15 Schering Corp Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
US6103735A (en) * 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
US6221880B1 (en) * 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US20030031720A1 (en) 2000-02-24 2003-02-13 Tobias Laich Method for producing pharmaceutical dosage forms
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
US8007830B2 (en) 2011-08-30
MXPA04003856A (es) 2004-07-08
EP1441701A1 (en) 2004-08-04
HRP20040367A2 (xx) 2005-06-30
KR101094084B1 (ko) 2011-12-15
KR20040047961A (ko) 2004-06-05
CA2463947C (en) 2009-05-19
ES2298431T3 (es) 2008-05-16
IL161299A0 (en) 2004-09-27
ECSP045082A (es) 2004-06-28
US20080131516A1 (en) 2008-06-05
EG24380A (en) 2009-04-05
HRP20040367B1 (en) 2012-07-31
DE60225040T2 (de) 2009-02-26
NO20042167L (no) 2004-05-25
DE60225040D1 (de) 2008-03-27
CN100591329C (zh) 2010-02-24
JP4420671B2 (ja) 2010-02-24
JP2005510497A (ja) 2005-04-21
DK1441701T3 (da) 2008-05-26
PT1441701E (pt) 2008-04-07
HUP0401670A2 (hu) 2008-05-28
HUP0401670A3 (en) 2008-08-28
EP1441701B1 (en) 2008-02-13
WO2003035036A1 (en) 2003-05-01
CA2463947A1 (en) 2003-05-01
MY148466A (en) 2013-04-30
CY1107400T1 (el) 2012-12-19
BR0213477A (pt) 2004-11-03
US20030096840A1 (en) 2003-05-22
ZA200402584B (en) 2005-06-29
ATE385781T1 (de) 2008-03-15
CN1575163A (zh) 2005-02-02
SI1441701T1 (sl) 2008-08-31
AU2002333134B2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
PE20030638A1 (es) Formulacion granular de montelukast sodico
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
NO20051688L (no) Farmasoytiske blandinger som har en modifisert baerer
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
HUP0402280A2 (hu) Mikronizált filmképző por, az ezt tartalmazó készítmények, eljárások ezek előállítására, és ezek alkalmazása
EA200500909A1 (ru) Модифицированное высвобождение фармацевтической композиции
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
BR0314687A (pt) Formulações farmacêuticas sólidas que compreendem telmissartano
DE60212163D1 (de) Kontrolliertes wirkstoffabgabesystem
PE58999A1 (es) Tabletas de oxacarbazepina recubiertas de pelicula
AR054806A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
AR037931A1 (es) Metodo para granulacion humeda de azitromicina
EE200200342A (et) Asendatud 8-arüülkinoliinid, nende kasutamine, farmatseutiline kompositsioon ja prekursorühend
NO20081721L (no) Stabil fast formulering av sertindol
DE60025503D1 (de) Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
EE200200252A (et) Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks
DE602004021704D1 (de) Wirksubstanzkombination mit einer verbindung mit npy rezeptor-affinität und einer verbindung mit 5-ht6 rezeptor-affinität
ATE301933T1 (de) Akarizidpulver
ATE359350T1 (de) Verdickte wässrige zusammensetzungen
AR031142A1 (es) Composiciones de limpieza
BRPI0516957A (pt) formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4)
WO2006008757A3 (en) Stabilized pharmaceutical compositions of pravastatin
BR0215925A (pt) Processo para converter um pó supressor de evaporação inicialmente não larvicida, de rápido espalhamento, em um pó supressor de evaporação larvicida, pó supressor de evaporação larvicida, modificação do processo, método e aperfeiçoamentos

Legal Events

Date Code Title Description
FG Grant, registration